

PATENT APPLICATION FEE DETERMINATION RECORD

Effective December 8, 2004

Application or Docket Number

10/539449

CLAIMS AS FILED - PART I

SMALL ENTITY
TYPE ☐ OR

OTHER THAN
SMALL ENTITY

	(Column 1)	(Column 2)
U.S. NATIONAL STAGE FEES		
BASIC FEE	SMALL ENT. = \$ 150	LARGE ENT. = \$ 300
EXAMINATION FEE	Satisfies PCT Article 33(1)-(4) = \$ 50 / \$ 100	All other situations = \$ 100 / \$ 200
SEARCH FEE	U.S. is ISA = \$ 50 / \$ 100 ALL other countries = \$ 200 / \$ 400	ALL other situations = \$ 250 / \$ 500
FEE FOR EXTRA SPEC. PGS.	minus 100 =	/ 50 =
TOTAL CHARGEABLE CLAIMS	23 minus 20 =	3
INDEPENDENT CLAIMS	1 minus 3 =	—
MULTIPLE DEPENDENT CLAIM PRESENT	<input type="checkbox"/>	

RATE	FEE
BASIC FEE	
EXAM. FEE	
SEARCH FEE	
X \$ 125 =	
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL	

RATE	FEE
BASIC FEE	300
EXAM. FEE	200
SEARCH FEE	400
X \$ 250 =	
X \$ 50 =	150
X \$ 200 =	
+ \$ 360 =	
TOTAL	1050

* If the difference in column 1 is less than zero, enter "0" in column 2

CLAIMS AS AMENDED - PART II

SMALL ENTITY OR

OTHER THAN
SMALL ENTITY

	(Column 1)	(Column 2)	(Column 3)
AMENDMENT A	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	* 34	Minus ** 23	= 11
Independent	* 1	Minus *** 3	= 0
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

RATE	ADDITIONAL FEE
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X \$ 50 =	550
X \$ 200 =	
+ \$ 360 =	
TOTAL ADDIT. FEE	

	(Column 1)	(Column 2)	(Column 3)
AMENDMENT B	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR	PRESENT EXTRA
Total	*	Minus **	=
Independent	*	Minus ***	=
FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <input type="checkbox"/>			

RATE	ADDITIONAL FEE
X \$ 25 =	
X \$ 100 =	
+ \$ 180 =	
TOTAL ADDIT. FEE	

RATE	ADDITIONAL FEE
X \$ 50 =	
X \$ 200 =	
+ \$ 360 =	
TOTAL ADDIT. FEE	

* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than "20", enter "20".

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than "3", enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

United States Patent and Trademark Office
- Sales Receipt -

06/02/2006 FMERCER 00000004 141263 10537449

01 FC:1202 550.00 DA

JUN 01 2006

CERTIFICATE OF FACSIMILE TRANSMISSION
I hereby certify that this correspondence is being facsimile transmitted to: Mail Stop Amendment Commissioner
for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, fax: 571-273-8300

Jessica Peña Date 6/1/06

Attorney Docket No.: 101215-189

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Brend Schwenzer
SERIAL NO. : 10/537,449
FILED : 01/09/2006
FOR : Polynucleotides Directed Towards hTERT and Use Thereof
ART UNIT : 1635
EXAMINER : Dana H. Shin

MAIL STOP AMENDMENT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

June 1, 2006

RESPONSE TO RESTRICTION REQUIREMENT

SIR:

This communication is in response to the Office Action dated May 2, 2006. It is being filed within the one month period for response.

Amendments to the Specification: None.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 6 of this paper.

1202-50X11-

USSN: 10/537,449
Response to Office Action dated
May 2, 2006
Atty Docket 101215-189

and a half of sequences, applicants target sequences are missing.

Cech et al. discloses a reduced telomerase activity in a cell by at least 50 % but lacks further details and exact experimental data. Contrary to that, the antisense oligonucleotides of the present application affect a reduction in viability of more than 65% (cf. Example 1). Furthermore, the oligos cause a synergistic booster effect if simultaneously administered with chemotherapeutics (cf. Example 2).

The inventors have previously prepared a paper manuscript further pointing out the unexpected benefits of their invention. The corresponding author proof is enclosed and further demonstrates the surprising benefits obtained by utilizing the specific sequences identified by the inventors.

Conclusion

Applicant believes these remarks and the claim amendments are sufficient to obviate the grounds for restriction presented in the outstanding office action and respectfully requests consideration of all the pending claims. Please charge any insufficiency of fees, or credit any excess, to Deposit Account No. 14-1263.

Respectfully submitted,

NORRIS McLAUGHLIN & MARCUS, P.A.

By 

Serle Ian Mosoff
Attorney for Applicant(s)
Reg. No. 25,900
875 Third Avenue - 18th Floor
New York, New York 10022